Inventor · disambiguated record
George D. Yancopoulos
Also filed as: KIMBLE CARRIE A · YANCOPOULOS GEORGE · YANCOPOULOS GEORGE D
200 granted patents·74 pending applications·7,581 citations·filing 1989–2025
99Inventor score
Top patents by PatentIndex Score
274 records- 0199US11730794B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2020·Granted Aug 22, 2023·8 cites·41 claims
- 0299US11707506B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2021·Granted Jul 25, 2023·5 cites·42 claims
- 0399US11559564B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2022·Granted Jan 24, 2023·5 cites·29 claims
- 0499US11253572B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2021·Granted Feb 22, 2022·11 cites·30 claims
- 0599US10888601B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2019·Granted Jan 12, 2021·14 cites·47 claims
- 0699US10857205B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2018·Granted Dec 8, 2020·14 cites·3 claims
- 0799US10828345B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2018·Granted Nov 10, 2020·19 cites·11 claims
- 0899US10392430B2Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2017·Granted Aug 27, 2019·37 cites·2 claims
- 0999US9708386B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2015·Granted Jul 18, 2017·41 cites·5 claims
- 1099US9546384B2Methods and compositions for the targeted modification of a mouse genomeREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·31 cites·26 claims
- 1199US9228208B2Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2014·Granted Jan 5, 2016·79 cites·24 claims
- 1299US8343737B2Cell culture compositions capable of producing a VEGF-binding fusion polypeptideREGENERON PHARMA·Filed 2011·Granted Jan 1, 2013·73 cites·12 claims
- 1399US8029791B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2008·Granted Oct 4, 2011·73 cites·9 claims
- 1499US7704500B2Methods of inhibiting ascites formation with modified chimeric VEGF polypeptidesREGENERON PHARMA·Filed 2008·Granted Apr 27, 2010·59 cites·8 claims
- 1599US7435553B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2006·Granted Oct 14, 2008·104 cites·15 claims
- 1699US7374757B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2004·Granted May 20, 2008·137 cites·7 claims
- 1799US7374758B2Modified chimeric polypeptides with improved pharmacokinetic properties and methods of using thereofREGENERON PHARMA·Filed 2004·Granted May 20, 2008·124 cites·3 claims
- 1899US7306799B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2005·Granted Dec 11, 2007·140 cites·11 claims
- 1999US7303747B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2005·Granted Dec 4, 2007·112 cites·6 claims
- 2099US7205148B2Genome mutation by intron insertion into an embryonic stem cell genomeREGENERON PHARMA·Filed 2004·Granted Apr 17, 2007·93 cites·9 claims
- 2199US7105348B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2002·Granted Sep 12, 2006·355 cites·15 claims
- 2299US7070959B1Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2000·Granted Jul 4, 2006·196 cites·15 claims
- 2399US6596541B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2001·Granted Jul 22, 2003·996 cites·17 claims
- 2499US6586251B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2000·Granted Jul 1, 2003·505 cites·14 claims
- 2598US10385359B2Targeted modification of rat genomeREGENERON PHARMA·Filed 2017·Granted Aug 20, 2019·29 cites·39 claims
- 2698US10208317B2Methods and compositions for the targeted modification of a mouse embryonic stem cell genomeREGENERON PHARMA·Filed 2016·Granted Feb 19, 2019·15 cites·61 claims
- 2798US10130681B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2017·Granted Nov 20, 2018·33 cites·26 claims
- 2898US9669069B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2015·Granted Jun 6, 2017·33 cites·12 claims
- 2998US9540449B2Anti-PCSK9 antibodies with pH-dependent binding characteristicsREGENERON PHARMA·Filed 2013·Granted Jan 10, 2017·57 cites·13 claims
- 3098US9254338B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2013·Granted Feb 9, 2016·38 cites·26 claims
- 3198US9139644B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2013·Granted Sep 22, 2015·44 cites·7 claims
- 3298US8791323B2Hybrid antibodies comprising human variable regions and mouse constant regions produced in a genetically modified mouseMURPHY ANDREW J·Filed 2006·Granted Jul 29, 2014·97 cites·3 claims
- 3398US8647842B2Methods for producing a fusion protein capable of binding VEGFPAPADOPOULOS NICHOLAS J·Filed 2012·Granted Feb 11, 2014·79 cites·14 claims
- 3498US8502018B2Methods of modifying eukaryotic cellsMURPHY ANDREW J·Filed 2011·Granted Aug 6, 2013·250 cites·20 claims
- 3598US7964377B2Nucleic acid molecule encoding a fusion polypeptide capable of binding VEGFREGENERON PHARMA·Filed 2008·Granted Jun 21, 2011·45 cites·8 claims
- 3698US7524499B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2008·Granted Apr 28, 2009·52 cites·3 claims
- 3798US7521049B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2007·Granted Apr 21, 2009·74 cites·15 claims
- 3898US7303746B2Methods of treating eye disorders with modified chimeric polypeptidesREGENERON PHARMA·Filed 2004·Granted Dec 4, 2007·117 cites·5 claims
- 3998US6927044B2IL-1 receptor based cytokine trapsREGENERON PHARMA·Filed 2002·Granted Aug 9, 2005·133 cites·30 claims
- 4097US10975139B1Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Apr 13, 2021·15 cites·20 claims
- 4197US10954289B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Mar 23, 2021·28 cites·28 claims
- 4297US10787501B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Sep 29, 2020·224 cites·20 claims
- 4397US10433527B2Genetically modified non-human animals and methods of use thereofREGENERON PHARMA·Filed 2018·Granted Oct 8, 2019·13 cites·12 claims
- 4497US8847004B2Humanized M-CSF miceMURPHY ANDREW J·Filed 2012·Granted Sep 30, 2014·28 cites·16 claims
- 4597US8759105B2Method for genetically modifying mouse embryonic stem cell by homologous recombinationECONOMIDES ARIS N·Filed 2007·Granted Jun 24, 2014·40 cites·10 claims
- 4697US8692052B2Genetically modified mice and engraftmentSTEVENS SEAN·Filed 2012·Granted Apr 8, 2014·22 cites·16 claims
- 4797US8541646B2Genetically modified mice and engraftmentSTEVENS SEAN·Filed 2010·Granted Sep 24, 2013·39 cites·17 claims
- 4897US8084234B2Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGFPAPADOPOULOS NICHOLAS J·Filed 2010·Granted Dec 27, 2011·54 cites·13 claims
- 4997US6919183B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2002·Granted Jul 19, 2005·88 cites·47 claims
- 5096US10815305B2Methods of treating inflammatory conditionsREGENERON PHARMA·Filed 2017·Granted Oct 27, 2020·11 cites·44 claims
Showing the top 50 of 274 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →